Is dasatinib 50 mg daily dose sufficient for treatment?

Dasatinib (Dasatinib), as a BCR::ABL1 tyrosine kinase inhibitor, has gained wide recognition in the treatment of chronic myeloid leukemia in the chronic phase (CML-CP). Recent research data indicate that compared with conventional treatment doses, a lower daily dose of 50 mg dasatinib may bring better tolerability and efficacy to patients.

A large-scale study that lasted5 years provides strong evidence. In this study, newly diagnosed CML-CP patients were enrolled and uniformly received 50 mg of dasatinib daily. The study results showed that in just 3 months, up to 96% of patients achieved a significant effect of reducing BCR::ABL1 transcript (IS) to less than 10%; and after 1 year, 81% of patients were still able to maintain a low level of BCR::ABL1 transcript (IS) below 0.1%. In addition, the study also showed that the treatment failure rate due to drug resistance or toxicity was only 5%, demonstrating the superior safety and tolerability of low-dose dasatinib. The 5-year overall survival rate was as high as 96%, and the event-free survival rate was also as high as 90%. During the entire study period, no patient experienced disease transformation into the accelerated phase or blast phase.

For pediatric patients with CML-CP, the latest clinical guidelines recommend determining the starting dose based on body weight, and reassessing the dose every 3 months, and even more frequent adjustments if necessary. This means that, while a daily dose of 50 mg may be sufficient in some adult patients, pediatric patients or patients with a lower body weight may require individualized dose adjustments based on their specific circumstances.

In summary, dasatinibDasatinib at a daily dose of 50 mg showed good efficacy and safety in the treatment of newly diagnosed CML-CP patients. However, the final dosage decision should still be made by the doctor based on the patient's specific situation, weight, condition and physical condition.